Dose-Ranging Study of an Ophthalamic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataract

A Randomized, Placebo-Controlled, Single-Masked, Dose-Ranging Study of C-KAD Ophthalmic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataracts

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00825721

Enrollment

Registered

2009-01-21

Start date

2007-11-30

Completion date

2009-09-30

Last updated

2009-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nuclear Cataract

Keywords

Cataract Study, Ophthalmic Study, Agerelated cataract, Nuclear Cataract, Low grade nuclear cataracts

Brief summary

This study will evaluate the safety and efficacy of three doses of C-KAD Ophthalmic Solution in patients with loss of visual function due to age-related nuclear cataract

Interventions

DRUGLiquiTears

4 drops applied daily for 360 days

DRUGC-KAD Ophthalmic Solution

4 drops applied daily for 360 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

35 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Presence of nuclear sclerosis cataract * BCDVA within the range of 20/40 and 20/80

Exclusion criteria

* Any other clinical condition in the eye that may compromise vision * Presence or history of glaucoma * Presence or history of diabetes * Use of eyedrops * Use of steroids

Design outcomes

Primary

Measure	Time frame
Best-corrected visual acuity by ETDRS	360 days

Countries

Nepal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026